Latest biopharmaceutical Stories

LA JOLLA, Calif., May 21, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the Deutsche Bank 38th Annual Healthcare Conference on Wednesday, May 29, 2013 at 3:30 pm EDT. The conference is being held at the Westin Boston...

--Demonstration of ASM-024 adjunctive benefit with current treatments in pre-clinical asthma models-- QUEBEC CITY, May 20, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced presentations of four studies of ASM-024, Asmacure's lead compound in development for asthma and chronic obstructive pulmonary disease...

QUEBEC CITY, May 16, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company will present four posters at the 2013 American Thoracic Society (ATS) International Conference, taking place May 17-22 in Philadelphia. All four will describe data around ASM-024, Asmacure's lead development compound,...

SEATTLE, COPENHAGEN, Denmark and SHANGHAI, May 14, 2013 /PRNewswire/ -- CMC Biologics today announced the execution of an agreement with RuiYi Inc. to develop a cell line for RYI-008, a novel anti-IL-6 monoclonal antibody. CMC Biologics' proprietary CHEF1® high-productivity expression plasmid will be utilized for the cell line development to optimize cell growth, and consistent, high-level protein expression in a rapid time frame. Specific terms of the agreement were not disclosed....

BELLEVILLE, ON, May 13, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has engaged U.S.-based Evercore Partners (Evercore) to assist the Board of Directors and management in its divestment of the Animal Health business. Evercore is a leading independent advisory firm in the U.S. that specializes in merger and acquisition transactions, divestitures and...

Two oral presentations at EULAR will review the impact of blisibimod on renal biomarkers and improved outcomes in systemic lupus erythematosus (SLE) patients HAYWARD, Calif., May 7, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced that additional data from its Phase 2b PEARL-SC study will be presented in two lecture sessions at the...

Keryx to Host Investor Conference Call on Wednesday, May 8, 2013 at 8:30am EDT NEW YORK, May 7, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the first quarter ended March 31, 2013. At March 31, 2013, the Company had cash and cash equivalents...

JUPITER, Fla., May 7, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the industrial enzyme, bioenergy, and biopharmaceutical industries, announced today that Danai Brooks will join the Company as Executive Vice President and Chief Operating Officer in June. Brooks joins Dyadic from J.P. Morgan where he served as a Vice President...

Investor Conference Call to be held Wednesday, May 8, 2013 at 8:30am EDT NEW YORK, May 6, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease, today announced that a conference call will be held on Wednesday, May 8, 2013 at 8:30 a.m. EDT to discuss results for the first quarter ended March 31, 2013...

HAYWARD, Calif., May 3, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, will release its first quarter 2013 financial report after market close on Monday, May 13(th). Anthera will host a Corporate Update conference call on May 20(th), 2013. Conference Call Access:Date: Monday, May 20(th), 2013Time: 5:00 pm Eastern Time Domestic Dial-in:...